Axitinib Licensed by Pfizer

Catalog No.S1005

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Price Stock Quantity  
USD 64 In stock
USD 70 In stock
USD 120 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Axitinib Chemical Structure

Axitinib Chemical Structure
Molecular Weight: 386.47

Validation & Quality Control

Customer Product Validation(4)

Quality Control & MSDS

Related Compound Libraries

VEGFR Inhibitors with Unique Features

Product Information

  • Compare VEGFR Inhibitors
    Compare VEGFR Products
  • Research Area
  • Axitinib Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Targets VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)

 View  More

IC50 0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM
In vitro Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cellNXfWWlYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIK0bXFKSzVyPUCuNFAxODVzMzFOwG0>M4i0UnNCVkeHUh?=
NCI-H1703MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrVR2NPUUN3ME2wMlAxODlyMjFOwG0>MoDrV2FPT0WU
KASUMI-1MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTkTWM2OD1yLkCwOlgzKM7:TR?=MkfPV2FPT0WU
CGTH-W-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3qNopLUUN3ME2wMlAxPzJ{IN88US=>NXHPTppzW0GQR1XS
A204Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnOcZBNUUN3ME2wMlAxQTl{IN88US=>NUf2NWo4W0GQR1XS
HOP-62MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3zTWM2OD1yLkGwPFM3KM7:TR?=M1fMSnNCVkeHUh?=
H-EMC-SSM4PkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTHTWM2OD1yLkGxNFA2KM7:TR?=NIfDPFNUSU6JRWK=
KU812Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILwUlVKSzVyPUCuNVY2PzdizszNNYmyW45MW0GQR1XS
EM-2MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjRTWM2OD1yLkG2PFE3KM7:TR?=MXnTRW5ITVJ?
LAMA-84NYXhdGd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnxTWM2OD1yLkG3OlY2KM7:TR?=NELNPYZUSU6JRWK=
JARMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDDTWM2OD1yLkKzPVg6KM7:TR?=Mmr5V2FPT0WU
G-361NFXYb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnXXlBLUUN3ME2wMlMzOzJ3IN88US=>MnHtV2FPT0WU
KG-1Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTBwM{e2OFIh|ryPNEL6XoFUSU6JRWK=
BV-173NYm5RWQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmPqTWM2OD1yLkO5N|Ih|ryPNFPZTHFUSU6JRWK=
K5NFvpcIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzHTWM2OD1yLkSyNVI4KM7:TR?=Mom0V2FPT0WU
MEG-01MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{TkXWlEPTB;MD60NlM3OSEQvF2=M1riXHNCVkeHUh?=
MFM-223MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoOyTWM2OD1yLkS0O|c3KM7:TR?=NX3hToZkW0GQR1XS
BE-13MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\3U2lEPTB;MD61NVAxQCEQvF2=MkXXV2FPT0WU
NEC8MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPwUXVRUUN3ME2wMlczOTF|IN88US=>MlHLV2FPT0WU
SW756MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHn0N2pKSzVyPUCuPVk5PDZizszNMkT1V2FPT0WU
A2780NHKwdWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFywPXFKSzVyPUGuNFEyPDZizszNMnLWV2FPT0WU
NB14NIXUfGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnP1TWM2OD1zLkCxPFAyKM7:TR?=MYfTRW5ITVJ?
H4MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHyTpFKSzVyPUGuNFY1OjJizszNNWLEe3UxW0GQR1XS
SK-OV-3MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTFwME[2N|Mh|ryPNGDt[HFUSU6JRWK=
AN3-CANVLEepZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnERow4UUN3ME2xMlA5Ozh7IN88US=>NVi3Nm5VW0GQR1XS
A427M{Pwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;2[YxKSzVyPUGuNVA{QDFizszNNULIdlVXW0GQR1XS
ES7M2joR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\CTmlEPTB;MT6xNVM{PCEQvF2=MoL5V2FPT0WU
AGSNWHhd|U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nvPWlEPTB;MT6xNVM6PSEQvF2=NEXvXHhUSU6JRWK=
G-402MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXGybHhCUUN3ME2xMlE1Pjl2IN88US=>M4HkfnNCVkeHUh?=
ES5NHnQe5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTFwMUeyOFgh|ryPMnyyV2FPT0WU
DELMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDMZZBKSzVyPUGuNlU1PTdizszNMnjEV2FPT0WU
NB10MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTFwM{K1OVch|ryPNGG3NlhUSU6JRWK=
NCI-H1581Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXKwNJVHUUN3ME2xMlM6ODR{IN88US=>NIfMRmdUSU6JRWK=
D-566MGM4P1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\QS2lEPTB;MT60NFY5OyEQvF2=NHLXWGNUSU6JRWK=
LXF-289NYDJV3BST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTX[WQxUUN3ME2xMlQ{QTl4IN88US=>M4\yU3NCVkeHUh?=
BT-549MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7CTWM2OD1zLkW2PVA6KM7:TR?=NWrX[W9iW0GQR1XS
NKM-1NHu3SY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTFwNkC1OVYh|ryPM3PoZnNCVkeHUh?=
SW780NEPBWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml3oTWM2OD1zLk[1NVU5KM7:TR?=MXXTRW5ITVJ?
NCI-H292NILy[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zWN2lEPTB;MT62OlM5OyEQvF2=M{ntWHNCVkeHUh?=
HMV-IIM{LoPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTFwN{C0PFgh|ryPNHXNPHBUSU6JRWK=
ALL-POM1q3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\MTWM2OD1zLkiwNFE2KM7:TR?=NUSxO|hlW0GQR1XS
UACC-257NXHPS45bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTFwOEKxOlMh|ryPMoSyV2FPT0WU
PA-1M3zlOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\yZ5dKSzVyPUGuPFI4OjVizszNNVn1R5lbW0GQR1XS
HD-MY-ZMkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjiZ2FKSzVyPUGuPFYzQDFizszNNHvqOIlUSU6JRWK=
HSC-4MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\qO2lEPTB;MT65N|g{QSEQvF2=MYTTRW5ITVJ?
GCTMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTJwMEC5NVYh|ryPM3rSfnNCVkeHUh?=
RT-112MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;aTWM2OD1{LkGzOFI1KM7:TR?=NGXtRWVUSU6JRWK=
A172NVe2XmJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTJwMUO2NFYh|ryPMVvTRW5ITVJ?
HCE-TNXzQSGp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfNTWM2OD1{LkKwOVk5KM7:TR?=NV\P[3Q5W0GQR1XS
YH-13Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInzPW9KSzVyPUKuNlE3PzFizszNNIHwVXlUSU6JRWK=
DK-MGNFS3XmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITrW49KSzVyPUKuNlM5OzRizszNNGLE[WNUSU6JRWK=
ACNMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTJwMkO4O|Uh|ryPMoDZV2FPT0WU
VA-ES-BJNVXmbZpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV2wUZpMUUN3ME2yMlI1QTV5IN88US=>NYq0bGw3W0GQR1XS
L-363MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HUbmlEPTB;Mj6yPFA3OSEQvF2=MmLVV2FPT0WU
HuH-7NF\BTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTJwNEKxOlUh|ryPMULTRW5ITVJ?
A4-FukMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnmNpVKSzVyPUKuOFcyPjhizszNNFHzXmVUSU6JRWK=
T-24NHzzPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LL[2lEPTB;Mj60PFA{PyEQvF2=NIHjfGdUSU6JRWK=
GOTOM3riPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzWTWM2OD1{LkWzNFE{KM7:TR?=NFjJbGRUSU6JRWK=
MV-4-11M2fvSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LnV2lEPTB;Mj61PVE3QSEQvF2=M{TqRnNCVkeHUh?=
DMS-114NFXFRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTJwNk[zOFUh|ryPNFPVeVBUSU6JRWK=
MHH-NB-11M2roc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnvtTWM2OD1{LkewNlk6KM7:TR?=NVnWUplpW0GQR1XS
CHP-212NYLG[ZFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjqTWM2OD1{LkiyNFkyKM7:TR?=NHLY[5pUSU6JRWK=
DMS-273MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnLOmJWUUN3ME2yMlkxOjB5IN88US=>NWf0TWVWW0GQR1XS
SF295M2HsS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\mRnBKSzVyPUOuNFI2QTdizszNM2LJfXNCVkeHUh?=
NCI-H1563M2e0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHvWldKSzVyPUOuNVUxODVizszNMlPBV2FPT0WU
NCI-H446MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzPNmlKSzVyPUOuNlI5ODVizszNMWjTRW5ITVJ?
HCC1806NVfCSlZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;4TWM2OD1|LkK3OlU4KM7:TR?=NWf1RllkW0GQR1XS
SF126NWO2Z|RNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjLSotKSzVyPUOuN|AxOTdizszNMUXTRW5ITVJ?
SW982MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\qRWlEPTB;Mz6zN|g4PSEQvF2=MWPTRW5ITVJ?
ES8MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTNwM{S5PVkh|ryPNUfxcoduW0GQR1XS
SCC-4NGTVW2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PvcWlEPTB;Mz61NFM6PiEQvF2=NETCUnBUSU6JRWK=
RPMI-8226MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2O5c2lEPTB;Mz62NlYyPiEQvF2=NGjOUGdUSU6JRWK=
EW-11Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHztbVdKSzVyPUOuOlMxOjJizszNMoj5V2FPT0WU
COR-L105MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnoXG1TUUN3ME2zMlY{OzN2IN88US=>NH[wbnhUSU6JRWK=
ES1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jB[GlEPTB;Mz64N|A6PCEQvF2=MmD6V2FPT0WU
KMOE-2NWn1b2F7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrUVFV1UUN3ME2zMlkyQDB6IN88US=>MmrZV2FPT0WU
ABC-1M1ftb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\uNG9KSzVyPUOuPVM6OTFizszNNEDPUI1USU6JRWK=
NCI-H526MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTNwOUmxNlYh|ryPNFjycIFUSU6JRWK=
HCC1395NGPFfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXGVotKSzVyPUOuPVk1QDRizszNNU\Oc2loW0GQR1XS
DU-145NFmyU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILt[W5KSzVyPUSuNVI5OjVizszNM{LqTnNCVkeHUh?=
JEG-3MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfsbJFKSzVyPUSuNVU6OTZizszNMknTV2FPT0WU
HCC1187MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTRwMkG1PVch|ryPM4ewfXNCVkeHUh?=
LC-2-adNFnFWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjFb2h{UUN3ME20MlIzOTd5IN88US=>Mnr3V2FPT0WU
ONS-76Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTRwMkSxPVIh|ryPNHztOldUSU6JRWK=
CAL-27MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3rV[mlEPTB;ND6yOFM1PCEQvF2=MkPMV2FPT0WU
8-MG-BAM3fJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zBfWlEPTB;ND6yOlY2QCEQvF2=NGXVWXlUSU6JRWK=
HGC-27MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3fxZmlEPTB;ND6yPVY3KM7:TR?=MoHTV2FPT0WU
Hs-578-TMkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3O5UWlEPTB;ND6zNVQ3QCEQvF2=Mn62V2FPT0WU
EW-1NF36NmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2[0SWlEPTB;ND61N|AyPCEQvF2=M3LTTnNCVkeHUh?=
SW1573NUW4UXZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFm5N4VKSzVyPUSuOVUyPjNizszNMVPTRW5ITVJ?
SNU-423NFLS[HVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HiSGlEPTB;ND62NFc6KM7:TR?=MmSyV2FPT0WU
HOSM2PB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\QVGlEPTB;ND62PVc4KM7:TR?=MXjTRW5ITVJ?
LB1047-RCCNVnaTWRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LJfWlEPTB;ND64NVQyQCEQvF2=NFPYXFVUSU6JRWK=
ChaGo-K-1NYLBeI9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTRwOEmwOFgh|ryPMUTTRW5ITVJ?
A3-KAWNVjnWno3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXK0Rnl1UUN3ME20Mlk4OzV{IN88US=>MVXTRW5ITVJ?
CAS-1NF2y[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH63TmxKSzVyPUSuPVk6ODhizszNMnywV2FPT0WU
NBsusSRMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTVwMEO1NVQh|ryPNXX4VWF6W0GQR1XS
KM12M3rFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmD4TWM2OD13LkK5PFI4KM7:TR?=NH\wW2ZUSU6JRWK=
NCI-H1155MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PEdGlEPTB;NT6zPFE5PSEQvF2=M2[0UXNCVkeHUh?=
EFM-19MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnG1TWM2OD13LkSxO|M4KM7:TR?=M3PF[nNCVkeHUh?=
D-392MGMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrRPJZ1UUN3ME21MlU4QDR7IN88US=>NFW5d2FUSU6JRWK=
JVM-3MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DUZmlEPTB;NT63NlMzPSEQvF2=MYTTRW5ITVJ?
EW-16MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTVwN{W1PFMh|ryPMnT4V2FPT0WU
KARPAS-45M4P1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfkfGRuUUN3ME21Mlg1OzJ3IN88US=>MWfTRW5ITVJ?
NCI-H28Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jYS2lEPTB;NT64O|kyQCEQvF2=MnLSV2FPT0WU
COLO-829MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1vVR2lEPTB;NT65NVUxPCEQvF2=MUnTRW5ITVJ?
KM-H2M1;4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmKxTWM2OD13LkmyN|k2KM7:TR?=MWrTRW5ITVJ?
NCI-H82MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrafVlKSzVyPUWuPVI4PzFizszNNF;jUnVUSU6JRWK=
OAW-42MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTVwOUi4NlEh|ryPMUTTRW5ITVJ?
A704NWrIdoxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXiUlNKSzVyPU[uNVA2PzRizszNMWrTRW5ITVJ?
NCI-H1048NXjaN29[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGf4ZXZKSzVyPU[uNVA2QTlizszNM36wdXNCVkeHUh?=
LOXIMVIM{\OZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;oUG5bUUN3ME22MlEyOjR6IN88US=>M4LYT3NCVkeHUh?=
MKN45MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTZwMk[wNVYh|ryPMVzTRW5ITVJ?
D-502MGNUGzc2dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zlNmlEPTB;Nj6yPFg2PyEQvF2=MonOV2FPT0WU
HUTU-80MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fM[mlEPTB;Nj60NVY5QCEQvF2=M33UWHNCVkeHUh?=
S-117Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTZwNUCyOlch|ryPMmnzV2FPT0WU
HCC1569Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTZwNUO3N|ch|ryPNX\jfFZKW0GQR1XS
J-RT3-T3-5M{\yemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1W2dmlEPTB;Nj61OFU4OiEQvF2=NYnvUoFFW0GQR1XS
OC-314M3\D[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXVTWM2OD14LkmxNVU6KM7:TR?=NFXQS2FUSU6JRWK=
SNU-449NYD2OZJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmD2TWM2OD15LkCxNFczKM7:TR?=MoXpV2FPT0WU
NCI-H720NYnxSHZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnpWFBbUUN3ME23MlE6OzR3IN88US=>MWrTRW5ITVJ?
KP-N-YSM4nn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzEOFZKSzVyPUeuNlA4OiEQvF2=MlvnV2FPT0WU
IGROV-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzsTWM2OD15LkOyN|g3KM7:TR?=Mln1V2FPT0WU
SK-PN-DWNWjlbG5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvQTWM2OD15LkS4NVUh|ryPMWHTRW5ITVJ?
HCC1419M{LtZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HreGlEPTB;Nz61N{DPxE1?M2jFT3NCVkeHUh?=
HAL-01NWDkPJBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTdwNkC2OFQh|ryPMV7TRW5ITVJ?
HCC2998NWTlU3NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DaRWlEPTB;Nz62NFc1OyEQvF2=M4PCNXNCVkeHUh?=
SK-N-FIMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mke4TWM2OD15Lk[zNFM{KM7:TR?=MnvwV2FPT0WU
GI-ME-NNYL6PHRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrVW4pvUUN3ME23MlY1QTN2IN88US=>M3:0XXNCVkeHUh?=
SW1088M2jqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHYTWM2OD15Lk[1PFI3KM7:TR?=NV7EN4d{W0GQR1XS
IA-LMNYnVTplCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETWXJZKSzVyPUeuOlg3OTNizszNNYX1OGhZW0GQR1XS
SK-NEP-1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjkTWM2OD15Lk[5OlEh|ryPMm\CV2FPT0WU
MDA-MB-415NGHGW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTdwOEmxPFYh|ryPMXTTRW5ITVJ?
COLO-800NHfLVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHl[5FKSzVyPUeuPVQ1QTJizszNNIHJc4hUSU6JRWK=
NCI-H2228NXH5XlZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M322cGlEPTB;OD6xOVc5OyEQvF2=Mo\JV2FPT0WU
D-423MGM4jW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\Pe5NKSzVyPUiuNlE4OiEQvF2=MVLTRW5ITVJ?
TE-1NGDv[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2XaNmlEPTB;OD60OFMyPiEQvF2=MorLV2FPT0WU
NOS-1NYS0Z|R{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;Wbmt6UUN3ME24MlUyPTN2IN88US=>M4rNeXNCVkeHUh?=
8505CMmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\kWGlEPTB;OD62OFgzPCEQvF2=Mn71V2FPT0WU
HEC-1M{D1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLVcGdFUUN3ME24Mlc5PDN7IN88US=>M{DrOnNCVkeHUh?=
TE-11NUXOOYF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRThwOUm1OVEh|ryPNES1b5NUSU6JRWK=
CTB-1NWmzTWlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PCdGlEPTB;OT6wNVQ{OyEQvF2=NYK1[VNGW0GQR1XS
TGBC11TKBMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX:3U2s2UUN3ME25MlAzOjRzIN88US=>M1\JOnNCVkeHUh?=
NB17NEfYPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXKTWM2OD17LkG4PFch|ryPM1rpVHNCVkeHUh?=
BeckerMoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTlwNEG5OFQh|ryPNYDkWXlbW0GQR1XS
SN12CNWW2[XFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoOzTWM2OD17LkS1NlM1KM7:TR?=NYXW[5ZkW0GQR1XS
COLO-320-HSRM1P6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlzwTWM2OD17Lk[wNlM4KM7:TR?=Mli1V2FPT0WU
D-283MEDMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTlwNkOwO|Ih|ryPMlvZV2FPT0WU
D-263MGMn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDocWNKSzVyPUmuPFM{QDRizszNNFHKVI9USU6JRWK=
MEL-JUSONV20ZXlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zpT2lEPTB;OT65NFEzPyEQvF2=MkLaV2FPT0WU
T98GMoT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XHVmlEPTB;OT65NFIxOyEQvF2=NHe4c5JUSU6JRWK=
HLENWPnc|hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7KPZpKSzVyPUmuPVA6ODlizszNNEn3dIpUSU6JRWK=
Ca9-22NVPtWlRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPUTWM2OD1zMD6wOlY2KM7:TR?=M3nNR3NCVkeHUh?=
OS-RC-2MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDhbnd3UUN3ME2xNE4yODR3IN88US=>M2\3PXNCVkeHUh?=
T47DNYn3ZmhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{Hk[mlEPTB;MUCuNVU2KM7:TR?=NUiyU5J1W0GQR1XS
GI-1M4fGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPsTWM2OD1zMD6zOVM{KM7:TR?=NWDPeXJNW0GQR1XS
NUGC-3M3ft[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTFyLkS0NFIh|ryPMo[4V2FPT0WU
MDA-MB-361MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;oTVhYUUN3ME2xNE41PDN{IN88US=>NGPLcWpUSU6JRWK=
SCC-15MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3P4OWlEPTB;MUCuOFcyQCEQvF2=M4\BVnNCVkeHUh?=
KS-1NFW3OndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTFyLk[zNFEh|ryPM1S1O3NCVkeHUh?=
CAL-12TM3vTdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7wTWM2OD1zMD62N|YyKM7:TR?=NHvU[Y5USU6JRWK=
OVCAR-4MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTFyLkewOlgh|ryPMoHnV2FPT0WU
HuP-T4MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTFzLkCzNlgh|ryPM2TU[3NCVkeHUh?=
NCI-H358Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXrOO4l2UUN3ME2xNU4zPjV5IN88US=>MXPTRW5ITVJ?
HO-1-N-1M2faT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYL1UFV1UUN3ME2xNU4{Ozl6IN88US=>Mk\lV2FPT0WU
NH-12NUXXdWl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH34W4lKSzVyPUGxMlU{PzhizszNMXvTRW5ITVJ?
MOLT-4M13rfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXZ[JlKSzVyPUGxMlU6QDVizszNNHT1VFZUSU6JRWK=
K-562M1TLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDtVpBKSzVyPUGxMlczPDhizszNNGrKemRUSU6JRWK=
ES6Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TaRmlEPTB;MUGuPFU5OSEQvF2=MV7TRW5ITVJ?
RO82-W-1M4PwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTFzLkmwOlQh|ryPNVH4WlNDW0GQR1XS
Ramos-2G6-4C10NH20NmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTFzLkmzNkDPxE1?NYTFS4doW0GQR1XS
23132-87MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\admlEPTB;MUKuNFgzOSEQvF2=M4r3N3NCVkeHUh?=
A549MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHFUGhKSzVyPUGyMlMzQDVizszNMXTTRW5ITVJ?
NCI-H23NGHueYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmnBTWM2OD1zMj61NFI3KM7:TR?=NHjub4JUSU6JRWK=
H9MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTF{LkW1O|ch|ryPNYDnW3hFW0GQR1XS
LB771-HNCMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTF{Lke2OUDPxE1?M37uTXNCVkeHUh?=
QIMR-WILMnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPmTG9KSzVyPUGyMlgzPThizszNM{j4VHNCVkeHUh?=
HSC-3NUDuUlZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnzW3VKSzVyPUGyMlkzPzZizszNNILjcIhUSU6JRWK=
PFSK-1M1fCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTMd4xKSzVyPUGyMlk2ODdizszNMWPTRW5ITVJ?
ETK-1MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTF|LkC3O|kh|ryPMkPLV2FPT0WU
SW1710NGL3b|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm[1TWM2OD1zMz6zOlQyKM7:TR?=MVfTRW5ITVJ?
COLO-684M1f3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\zTm9mUUN3ME2xN{41PTRzIN88US=>NIPqfpFUSU6JRWK=
RPMI-7951NX3Xe3pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrxVVBKSzVyPUGzMlUyOzZizszNNX\Ld4dRW0GQR1XS
A101DM3vxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnvTWM2OD1zMz61N|Q6KM7:TR?=M4PjSHNCVkeHUh?=
KE-37MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jNd2lEPTB;MUOuOVg5PyEQvF2=MlTMV2FPT0WU
SiHaM{W2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFvKW2FKSzVyPUGzMlg{PDZizszNMkDoV2FPT0WU
NCI-H226M2TROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGOzbXpKSzVyPUGzMlg5ODhizszNNHHuUYZUSU6JRWK=
DBNYjwZo9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\zTphKSzVyPUGzMlk6OjhizszNM3S1fHNCVkeHUh?=
HT-1197MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoT4TWM2OD1zND6wPFA6KM7:TR?=MWTTRW5ITVJ?
SBC-5NFvuSFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTF2LkGzOlIh|ryPM3zr[nNCVkeHUh?=
VMRC-RCZNI\pSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkG5TWM2OD1zND61O|c1KM7:TR?=MYHTRW5ITVJ?
697NGrUUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLCSI9MUUN3ME2xOE43OjdizszNNF:yNVZUSU6JRWK=
OMC-1M3[0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfCTWM2OD1zND63PFg5KM7:TR?=MVfTRW5ITVJ?
SKG-IIIaMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTF2LkiwNFEh|ryPNWPmXZV[W0GQR1XS
DOKMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\sTWM2OD1zND65PVM{KM7:TR?=NXywbot5W0GQR1XS
NCI-H2029MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEf6dZhKSzVyPUG1MlM3ODJizszNM1;uRXNCVkeHUh?=
NCI-H2009NGP3[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWD4S4hIUUN3ME2xOU42ODl3IN88US=>MlzWV2FPT0WU
LK-2MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmrDTWM2OD1zNT62OFQ6KM7:TR?=M4H2O3NCVkeHUh?=
NCI-H661NHGyWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3P6R2lEPTB;MUWuPVA4PSEQvF2=M{jyNHNCVkeHUh?=
GT3TKBNYe3R21zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTF4LkC2O|Yh|ryPNGfVSlBUSU6JRWK=
GP5dNXj5eVd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\PTGlEPTB;MU[uN|QzKM7:TR?=M1TZfHNCVkeHUh?=
SK-MEL-2M37lSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fWT2lEPTB;MU[uOFQ5PSEQvF2=NH30d|hUSU6JRWK=
SK-UT-1M2rje2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXmyco8zUUN3ME2xOk42PjVizszNNY\jOYIxW0GQR1XS
NB7Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTF4Lk[5O|Eh|ryPMl7nV2FPT0WU
NCI-H460MoKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVn0bFhQUUN3ME2xOk44OzJ4IN88US=>NWO2fIhqW0GQR1XS
8305CMlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nVdWlEPTB;MU[uO|g4PyEQvF2=NW\TTIFrW0GQR1XS
CaR-1NFTKZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nMdWlEPTB;MU[uPFEyOSEQvF2=NUTCO2ViW0GQR1XS
D-247MGNXXmNW5UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTF4Lki2NlUh|ryPNHraOldUSU6JRWK=
LoVoMmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TMZWlEPTB;MU[uPVQ5QCEQvF2=MV3TRW5ITVJ?
NCI-H2405NVzZSFdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYnaWW14UUN3ME2xO{4yQTB6IN88US=>M1GwTHNCVkeHUh?=
AU565NYLBOJhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{W2OmlEPTB;MUeuNlI2KM7:TR?=MYnTRW5ITVJ?
OCI-AML2MkPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIf3S2lKSzVyPUG3MlU{OTdizszNNI\wb3pUSU6JRWK=
22RV1Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGj2bIJKSzVyPUG3MlU5QDRizszNM33jNHNCVkeHUh?=
HT-144MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTF5Lk[1PVgh|ryPNInUVlRUSU6JRWK=
HuO9MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7RTWM2OD1zNz63NFMyKM7:TR?=M{XmRXNCVkeHUh?=
DaoyNHT4d5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2[zO2lEPTB;MUeuO|E5PCEQvF2=NV\XfFhMW0GQR1XS
SJRH30NXu0bVdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGX4fpZKSzVyPUG3Mlg1QDlizszNMYnTRW5ITVJ?
CHL-1MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fCemlEPTB;MUeuPVI1QSEQvF2=MVvTRW5ITVJ?
J82MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{XC[mlEPTB;MUeuPVY{PSEQvF2=NFLofopUSU6JRWK=
COR-L23M170cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{O2bGlEPTB;MUiuNFAyOSEQvF2=M4e3NXNCVkeHUh?=
SNU-C2BMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXwTWM2OD1zOD6yNlc3KM7:TR?=NY\kSWdOW0GQR1XS
NCI-H1770NFzJbJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFf4Z2JKSzVyPUG4MlQ3OTVizszNMlPkV2FPT0WU
MHH-PREB-1M3iwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIrnWZNKSzVyPUG4MlU3QTdizszNMmrEV2FPT0WU
ES3NVGwR5lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDlT4ZKSzVyPUG4MlU5QDNizszNNID5XGdUSU6JRWK=
MDA-MB-231NWq4SHo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4jYSmlEPTB;MUiuOlUxOiEQvF2=MYDTRW5ITVJ?
MN-60MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPJOmFFUUN3ME2xPU4xPTl{IN88US=>NUThXpZCW0GQR1XS
EPLC-272HNFrJW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTF7LkO3NFgh|ryPMlG1V2FPT0WU
SW948MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTF7LkO5N|Qh|ryPMUDTRW5ITVJ?
MOLT-13Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fDc2lEPTB;MUmuOFU1PiEQvF2=NGLrOVFUSU6JRWK=
HL-60Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nCWGlEPTB;MkCuNlE1OSEQvF2=M3;vcHNCVkeHUh?=
CP50-MEL-BM13rNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LDZWlEPTB;MkCuOFc1QCEQvF2=MmjDV2FPT0WU
NTERA-S-cl-D1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXMVlhNUUN3ME2yNE41QTd6IN88US=>NGXRNZVUSU6JRWK=
KINGS-1NG\1doFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILoWJJKSzVyPUKwMlc6PjdizszNNV7wVmhKW0GQR1XS
DOHH-2NYTTSpBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlW3TWM2OD1{MD65NFYh|ryPMUDTRW5ITVJ?
BB65-RCCNILB[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XEbmlEPTB;MkCuPVI5PSEQvF2=MWXTRW5ITVJ?
NB12NFTwZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLHTnlKSzVyPUKxMlA{QTRizszNMnfRV2FPT0WU
KY821MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX70RolbUUN3ME2yNU42QDJizszNNXHx[2R1W0GQR1XS
PSN1NHvWOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XtWWlEPTB;MkGuOlQ2OyEQvF2=NVvONJR4W0GQR1XS
EGI-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTJzLke0OVQh|ryPNFfs[nBUSU6JRWK=
CTV-1M1r1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTQbYhLUUN3ME2yNk4{ODNzIN88US=>M1\vZnNCVkeHUh?=
TI-73M{DXemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTJ{LkO0PVgh|ryPNXy4V|BzW0GQR1XS
LCLC-103HMlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkniTWM2OD1{Mj60O|UzKM7:TR?=NGXRNWdUSU6JRWK=
D-542MGNVXzO3RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmSzTWM2OD1{Mj61OVU5KM7:TR?=MVLTRW5ITVJ?
ATN-1NX7GSI5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\M[WlEPTB;MkKuOlQ{QSEQvF2=M2f1WHNCVkeHUh?=
SK-MEL-1NHjYUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfodXVKSzVyPUKyMlg{PjhizszNMXLTRW5ITVJ?
HDLM-2MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnDOGlxUUN3ME2yN{4yPDd6IN88US=>NImzUlhUSU6JRWK=
UM-UC-3NFTXNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVi4SFh[UUN3ME2yN{4yQTR2IN88US=>NFTQOpFUSU6JRWK=
NCI-H1573NVfoVmtGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTJ|LkS2PFEh|ryPM4\QbHNCVkeHUh?=
NCI-H520MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInScIxKSzVyPUKzMlQ6PDhizszNMmHlV2FPT0WU
ESS-1NFnvXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjQRlhbUUN3ME2yN{45ODV7IN88US=>MlPvV2FPT0WU
COR-L88NEjTbYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnL3TWM2OD1{Mz65OFc2KM7:TR?=NFXuRXVUSU6JRWK=
TGBC24TKBMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3;nT2lEPTB;MkSuNFMyOiEQvF2=M3v2enNCVkeHUh?=
HCC1937NYfjOYd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGX5UINKSzVyPUK0MlEh|ryPNGPieVhUSU6JRWK=
RS4-11NEPjS3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXZ[XJKSzVyPUK0MlE1OiEQvF2=MmrxV2FPT0WU
HCC38MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjiNZVKSzVyPUK0MlI{QTRizszNMVzTRW5ITVJ?
RPMI-2650NIK0TZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTJ2Lk[xOlIh|ryPNHTNNGZUSU6JRWK=
P12-ICHIKAWANVjQfIF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17McmlEPTB;MkSuOlI2QCEQvF2=M3zCNnNCVkeHUh?=
YAPCNFS5PItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33ZfWlEPTB;MkSuPFIyPCEQvF2=NGHP[pVUSU6JRWK=
NB13M{jWSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XwR2lEPTB;MkWuNlYyOSEQvF2=NX;Cb2hZW0GQR1XS
SK-N-ASMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTJ3Lki1PFQh|ryPMkjJV2FPT0WU
SK-N-DZNET0c4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTJ4LkC0PUDPxE1?NYHLd2FHW0GQR1XS
LS-411NM{Dt[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFi5cmFKSzVyPUK2MlIxOzhizszNNFXxUGhUSU6JRWK=
NCI-H810MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoK5TWM2OD1{Nj6zNVEzKM7:TR?=M2[yPHNCVkeHUh?=
NCI-SNU-1Mnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2fPSGlEPTB;Mk[uOVQ2PCEQvF2=NVzWeGt[W0GQR1XS
HHNV\K[oxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPZTWM2OD1{Nj61OVI6KM7:TR?=NYnSUmFXW0GQR1XS
U-2-OSMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTJ4LkezPFIh|ryPMXfTRW5ITVJ?
SF539NYrNO4t{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWi1bZZOUUN3ME2yOk45ODF6IN88US=>NV3hN2s6W0GQR1XS
NCI-H2052NXW1cXBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInDZmJKSzVyPUK3MlA5PiEQvF2=NVv5WnI6W0GQR1XS
A673MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\HbJJKSzVyPUK3MlIyODJizszNMnzvV2FPT0WU
WM-115NXT3NlNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjyemZqUUN3ME2yO{44PzZ5IN88US=>NHW2VpVUSU6JRWK=
SW48Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYf3cI9wUUN3ME2yO{45ODB3IN88US=>NF3qSHdUSU6JRWK=
NOMO-1NEi4b21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvWdJlKSzVyPUK3Mlg2OzJizszNM{naWnNCVkeHUh?=
PC-3NXTUeXhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{G2cGlEPTB;MkeuPFk1OSEQvF2=MYLTRW5ITVJ?
UMC-11MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPDUHN2UUN3ME2yO{46OzR|IN88US=>MXHTRW5ITVJ?
U-118-MGNHruSZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rXUWlEPTB;MkiuNFEzOyEQvF2=MWfTRW5ITVJ?
NCI-H2452M2\KXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHj5OGhKSzVyPUK4MlA5OjJizszNM4DJenNCVkeHUh?=
CAMA-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGj0SlhKSzVyPUK4Mlg2PjRizszNMYjTRW5ITVJ?
MC-IXCNWL0cFN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTJ7LkKzOlYh|ryPNGL5eZRUSU6JRWK=
ES4M2\pR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlS2TWM2OD1{OT6zNVczKM7:TR?=M3rxRnNCVkeHUh?=
BHT-101Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEnGc3VKSzVyPUK5MlMzOSEQvF2=Mor3V2FPT0WU
KP-4MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DHdGlEPTB;MkmuOVE3KM7:TR?=MV\TRW5ITVJ?
CAL-54MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M364T2lEPTB;MkmuOVQ1PSEQvF2=NUj0S4RjW0GQR1XS
5637NHGwVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17aNWlEPTB;MkmuOlQzOSEQvF2=M4O4fnNCVkeHUh?=
MOLT-16NGjLOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHzVZExUUN3ME2yPU44OjZ7IN88US=>MX\TRW5ITVJ?
Ca-SkiNX24cIxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHe0bWdKSzVyPUK5Mlk1PiEQvF2=NFzFN2tUSU6JRWK=
AsPC-1MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHO4OWtKSzVyPUOwMlAzOTJizszNMmjYV2FPT0WU
MSTO-211HMkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDRbWVbUUN3ME2zNE4yPSEQvF2=NWfTNJdxW0GQR1XS
L-428M2m4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jNV2lEPTB;M{CuOFA2KM7:TR?=NIPpfY5USU6JRWK=
SW1463MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DNfmlEPTB;M{CuOVM5OyEQvF2=NFGx[YpUSU6JRWK=
NCI-H1648NYfmO5RCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4XrRWlEPTB;M{CuOVU4PCEQvF2=MXnTRW5ITVJ?
CAKI-1MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoG2TWM2OD1|MD63O|AzKM7:TR?=M4C0[HNCVkeHUh?=
YKG-1Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTNzLkCyOlMh|ryPNG\vSYtUSU6JRWK=
A2058NVrnUZhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\tTWM2OD1|MT6xNVY1KM7:TR?=NHjsbYlUSU6JRWK=
A375M3HWdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTNzLkG2PVYh|ryPNIDqRm1USU6JRWK=
SNB75MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInwSphKSzVyPUOxMlI1OzVizszNNF;xRVhUSU6JRWK=
SK-HEP-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2OxZ2lEPTB;M{GuOFI4OSEQvF2=M4\1eHNCVkeHUh?=
ME-180MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXwTWM2OD1|MT62OVQzKM7:TR?=NEKxVoFUSU6JRWK=
NCI-H209M{LReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXYTWM2OD1|MT64NlQ4KM7:TR?=M1\RXXNCVkeHUh?=
HC-1NV:5TIlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LVUmlEPTB;M{KuNVQ1PiEQvF2=NGT4VlBUSU6JRWK=
LB373-MEL-DMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DsNGlEPTB;M{KuNVk4OSEQvF2=M3PrenNCVkeHUh?=
SNU-387M2fKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTqTWM2OD1|Mj6zNVkyKM7:TR?=MWjTRW5ITVJ?
C32NHjWXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkjvTWM2OD1|Mj6zN|U{KM7:TR?=M4DxXnNCVkeHUh?=
EW-13M4Todmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHzTWlFKSzVyPUOyMlk1ODhizszNM{PZNnNCVkeHUh?=
BFTC-905MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7tTWM2OD1|Mz61NVM3KM7:TR?=NV;NUHdVW0GQR1XS
NCI-H1299M3jkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTN|LkW2NlEh|ryPNE\DVGZUSU6JRWK=
LU-135NIH4bWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXe0OWdGUUN3ME2zN{45ODFizszNM4fDOHNCVkeHUh?=
NCI-H2122MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DBNWlEPTB;M{OuPVk3PiEQvF2=MoPVV2FPT0WU
SK-LMS-1NFL4UJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFnxTGxKSzVyPUO0MlQyODdizszNMYPTRW5ITVJ?
LNCaP-Clone-FGCM1HPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;jem5KSzVyPUO0Mlg2OTVizszNMVXTRW5ITVJ?
NCI-H1092MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYS4cmFvUUN3ME2zOU4zPzR5IN88US=>NXH0eWZDW0GQR1XS
MS-1NV;MUW5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HwPGlEPTB;M{WuN|A{QCEQvF2=NVnJPFVvW0GQR1XS
KYSE-510M{\CeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjXTWM2OD1|NT61NFQzKM7:TR?=MmLoV2FPT0WU
NCI-H1793M1[xRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nlO2lEPTB;M{WuOlU1PSEQvF2=NU\qOG0{W0GQR1XS
MIA-PaCa-2NYnWZXRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TqSWlEPTB;M{[uNFQ6PiEQvF2=NIjLOnVUSU6JRWK=
EW-22MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTCNVd3UUN3ME2zOk41ODd{IN88US=>NYHJXVliW0GQR1XS
IGR-1M3nJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DoemlEPTB;M{[uPFE5PCEQvF2=NWjwT2VxW0GQR1XS
HT-1080NGLZUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\qTWM2OD1|Nz6xNlUh|ryPMYrTRW5ITVJ?
M14NXv2[FdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTN5LkG2OFIh|ryPNVfvdldYW0GQR1XS
786-0NHLISItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NES1T3FKSzVyPUO3MlI4QTRizszNM3zS[3NCVkeHUh?=
MZ2-MELMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLJTWM2OD1|Nz60OVAyKM7:TR?=NGT5VIpUSU6JRWK=
NCI-H510AMkjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PTfWlEPTB;M{euPVQyOiEQvF2=NEGwcYdUSU6JRWK=
LAN-6MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvuNoMxUUN3ME2zO{46PTh{IN88US=>NH7lZ41USU6JRWK=
SW620M2TmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DCVmlEPTB;M{iuOFk4PCEQvF2=MYTTRW5ITVJ?
LB2241-RCCM4\pXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;IcFVqUUN3ME2zPU45OjB3IN88US=>NX;pZZlzW0GQR1XS
Detroit562MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTRyLkGyOlgh|ryPMY\TRW5ITVJ?
HNM2XTU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTRyLkG3PFIh|ryPMknMV2FPT0WU
HCT-15NGqxTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2mxWWlEPTB;NECuOVkxPyEQvF2=MV;TRW5ITVJ?
C2BBe1NUDDSW1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFexWXFKSzVyPUSwMlkyPTdizszNM1nC[nNCVkeHUh?=
A498M2DVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nIemlEPTB;NEGuN|AyPSEQvF2=MWrTRW5ITVJ?
SK-MEL-24NUHqbI5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2i1UGlEPTB;NEGuOFczPSEQvF2=NXPEN3RoW0GQR1XS
OVCAR-5M4n2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIrXbnRKSzVyPUSxMlc4PjdizszNMkT5V2FPT0WU
NCI-H1792MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTJeHZjUUN3ME20NU46QDJzIN88US=>NWrVPJA3W0GQR1XS
KOSC-2MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYG2c3RyUUN3ME20Nk4zPjl7IN88US=>NYHpb5ptW0GQR1XS
Mo-TMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnsZ3c5UUN3ME20Nk45QTV6IN88US=>Moj5V2FPT0WU
CFPAC-1NHzYUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHRZWFKSzVyPUSzMlQ6PDRizszNMm\iV2FPT0WU
CAL-51M{HCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnvfYlKSzVyPUSzMlU3ODVizszNM3HhOHNCVkeHUh?=
RH-18NEHkWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfGWFNKSzVyPUSzMlgxPSEQvF2=MoLKV2FPT0WU
EC-GI-10MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XnXWlEPTB;NEOuPFM1PyEQvF2=NFvtU|hUSU6JRWK=
HSC-2M{LUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XCTWlEPTB;NESuNFA6KM7:TR?=NYmxdJBZW0GQR1XS
ML-2MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTZUFJKSzVyPUS1MlI3OjFizszNMVTTRW5ITVJ?
KNS-81-FDMlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTR3LkezOlUh|ryPMkTKV2FPT0WU
NB6MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jqO2lEPTB;NE[uNVEyKM7:TR?=NWrlbXp7W0GQR1XS
MCF7M1XaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MonXTWM2OD12Nj61OVM{KM7:TR?=M1zzZXNCVkeHUh?=
P30-OHKMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHSyUYRKSzVyPUS2MlgyOTdizszNM4\0WHNCVkeHUh?=
BPH-1NGDEeIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rwW2lEPTB;NE[uPVgxPSEQvF2=MYHTRW5ITVJ?
U251MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjheopzUUN3ME20Ok46QTRizszNNWK3Zm4zW0GQR1XS
MKN1NFPWUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGPvZm9KSzVyPUS3MlUyOzdizszNMVPTRW5ITVJ?
A431NYPtb4E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rJeGlEPTB;NEeuPFM{QCEQvF2=NIXBRlhUSU6JRWK=
C8166M1HkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEKwdWxKSzVyPUS5MlIxOzlizszNMl\ZV2FPT0WU
HELMoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGL0dGJKSzVyPUS5MlQxPjRizszNMkTFV2FPT0WU
RMG-IM4LXSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTR7LkS0OFQh|ryPMWTTRW5ITVJ?
CAL-72NX[5V4xFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\rfZNbUUN3ME20PU43ODd3IN88US=>NEe3c2NUSU6JRWK=
SW962NW\uXXQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;4eWlEPTB;NEmuPVM{OiEQvF2=MoPlV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).

Protocol(Only for Reference)

Kinase Assay:

[1]

Cellular receptor kinase phosphorylation assay Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.

Cell Assay:

[2]

Cell lines HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
Concentrations 1 nM - 10 μM
Incubation Time 72 hours
Method

Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.

Animal Study:

[3]

Animal Models BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
Formulation 0.5% carboxymethylcellulose (CMC)
Dosages 10, 30 or 100 mg/kg
Administration Oral daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Hu-Lowe DD, et al. Clin Cancer Res, 2008, 14(22), 7272-7283.

[2] Rossler, J. et al., Int J Cancer, 2011, 128(11), 2748-2758.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-04-16)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02156895 Not yet recruiting Advanced Renal Cell Carcinoma Pfizer December 2016 --
NCT02684006 Recruiting Renal Cell Cancer Pfizer March 2016 Phase 3
NCT02636725 Recruiting Alveolar Soft Part Sarcoma|Soft Tissue Sarcomas Breelyn Wilky|Merck Sharp & Dohme Corp.|Pfizer|University  ...more Breelyn Wilky|Merck Sharp & Dohme Corp.|Pfizer|University of Miami March 2016 Phase 2
NCT02693535 Recruiting Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors American Society of Clinical Oncology|AstraZeneca|Bayer|B  ...more American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Pfizer March 2016 Phase 2
NCT02639182 Not yet recruiting Metastatic Renal Cell Carcinoma Agensys, Inc.|Astellas Pharma Inc January 2016 Phase 2

view more

Chemical Information

Download Axitinib SDF
Molecular Weight (MW) 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms AG 013736
Solubility (25°C) * In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% CMC 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide

Customer Product Validation (4)


Click to enlarge
Rating
Source J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck
Method Spheroid Staining & Sectioning
Cell Lines MDA-MB-231 cells
Concentrations 10 µM
Incubation Time 72 h
Results These results demonstrate that both U0126 and axitinib penetrated into the spheroid, resulting in downregulation of vimentin throughout the whole spheroid by more than 80% as compared to untreated spheroids.

Click to enlarge
Rating
Source J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck
Method Western Blot
Cell Lines MDA-MB-231 cells
Concentrations 10 µM
Incubation Time
Results Based on these data, there appears to be a threshold of 50% downregulation of VimPro-Fluc activity that must be reached before protein downregulation occurs.

Click to enlarge
Rating
Source J Biomol Screen 2011 16, 141-154. Axitinib purchased from Selleck
Method Secondary assay
Cell Lines MDA-MB-231 cells
Concentrations 10 µM
Incubation Time
Results U0126, pF2341066, axitinib, and pKC412 caused significant inhibition of the invasive potential of Mda-Mb-231 spheroids. Conversely, dasatinib, a potent inhibitor of vimentin gene expression, did not significantly alter the invasive potential of MDA-MB-231 spheroids.

Click to enlarge
Rating
Source Dr. Cheri Pasch of UW Madison. Axitinib purchased from Selleck
Method Western blot
Cell Lines HUVEC cells
Concentrations 0.1-10 nM
Incubation Time
Results Axitinib treatment blocks VEGFR2 phosphorylation.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related VEGFR Products

  • SU5402

    SU5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGF-Rβ, respectively.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • Regorafenib (BAY 73-4506)

    Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

  • Cabozantinib (XL184, BMS-907351)

    Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.

  • Nintedanib (BIBF 1120)

    Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.

  • Vandetanib (ZD6474)

    Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay.

  • Lenvatinib (E7080)

    Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β in cell-free assays. Phase 3.

  • Pazopanib

    Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

  • Pazopanib HCl (GW786034 HCl)

    Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

    Features:A multi-kinase inhibitor.

Recently Viewed Items

Tags: buy Axitinib | Axitinib ic50 | Axitinib price | Axitinib cost | Axitinib solubility dmso | Axitinib purchase | Axitinib manufacturer | Axitinib research buy | Axitinib order | Axitinib mouse | Axitinib chemical structure | Axitinib mw | Axitinib molecular weight | Axitinib datasheet | Axitinib supplier | Axitinib in vitro | Axitinib cell line | Axitinib concentration | Axitinib nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us